Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
New Blood Test Poised to Revolutionize Care for Systemic Lupus Erythematosus
Local Company’s Blood Test Will Change Lupus Care
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Digital Dialogue: Lupus Awareness Month
LuGENE® Launches for Lupus
LUPUS FEATURES
Monitoring Lupus with Data: a discussion with Dr. Schneider(Stanford) & Dr. Grammer (AMPEL’s LuGENE Flare Blood Test)
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus. Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI.
New Blood Test Poised to Revolutionize Care for Systemic Lupus Erythematosus
AMPEL BioSolutions announced the launch of LuGENE®, an exciting breakthrough innovation in systematic lupus erythematosus (SLE) care. LuGENE® is a new blood test designed to predict SLE flares before they happen and provide specific information about each individual’s disease abnormalities, leading to faster, evidence-based treatment.
AMPEL BioSolutions Building Evidence for Prognostic Potential of Lupus Molecular Subtyping Test
AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations.
LuGENE blood test may help personalize treatment for lupus
Ampel BioSolutions is launching LuGENE, a blood test that uses artificial intelligence (AI) to look at a patient’s gene activity and predict when lupus flares are likely to happen and which medications could be most effective to keep symptoms in check.
Revolutionizing Lupus Care with Advanced Predictive Blood Testing
AMPEL BioSolutions introduces LuGENE®, a cutting-edge blood test poised to revolutionize the management of systematic lupus erythematosus (SLE). LuGENE® leverages predictive artificial intelligence (AI) to detect genetic biomarkers indicative of inflammation-driven SLE flares, offering clinicians valuable insights for tailored treatment strategies.
New Lupus Test Predicts Flares & Drug Targets
From RNA gene expression in cells circulating in the blood, LuGENE identifies real-time abnormalities leading to inflammation and immune system dysfunction that are targetable by medication.
A new tool in the fight against autoimmune disease lupus
There is a new way to detect lupus before it causes more significant damage. LuGENE, a new blood test by AMPEL BioSolutions, helps forecast flare-ups and recognizes targets for effective drug options based on genomic data it reveals.
New blood test predicts flares before they happen
Ampel Biosolutions announced the launch of LuGENE®, a blood test that uses artificial intelligence (AI) to look at a patient’s gene activity and predict when lupus flares are likely to happen and which medications could be most effective to keep symptoms in check.
LuGENE Launches in LA: Podcast with Dr. Dan Wallace
This #NewsFromTheLab session welcomes the creators of the new LuGENE lab test by Ampel BioSolutions! Watch Dr. Amrie Grammer and Dr. Peter Lipsky share about the cutting-edge LuGENE® Blood Test, a revolutionary tool designed to predict flare activity and drug targets in lupus, offering new hope and possibilities for patients.
Precision Medicine in Action: New Blood Test May Predict Lupus Flares, Eliminate Treatment Trial and Error
AMPEL BioSolutions’ LuGENE blood test may help predict lupus flares and drug targets from gene expression utilizing predictive artificial intelligence (AI).
A Chase for More Precise Brand of Medication
Well, you see, more than 95 percent Lupus patients have experienced a flare of symptoms in the last year. Hence, in response, the new LuGENE® test identifies real-time abnormalities leading to inflammation and immune system dysfunction, abnormalities that are especially targetable by medication.
LuGENE blood test for lupus flares, drug targets enters open-label study
LuGENE, a blood test to predict lupus flares and quickly identify drug targets, is being made available to patients around the United States through an open-label study, according to a press release from the manufacturer.
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
Connect with Intent – Ampel BioSolutions
A while back we spoke with Amrie Grammer, President of Ampel BioSolutions about their precision medicine solutions for Lupus patients and their care teams. We’re excited to bring her back alongside Angel Derricott, Lupus advocate, to speak on their progress.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares from a Blood Sample
Local Company’s Blood Test Will Change Lupus Care
A local precision medicine and science company launched a test that will change the way lupus patients get care. AMPEL BioSolutions created a blood test called LuGENE. It will predict if someone is likely to have a lupus flare.
LuGENE® Launches for Lupus
During this interview with Scripps News Network, Dr. Grammer explains how there is currently no way to predict flares or determine which is the most appropriate treatment for an individual lupus patient. Identifying a therapeutic regimen that stabilizes a patient’s disease course often takes several years of trial and error.
Q&A: UVA-Trained Biotech Leader Setting Her Sights on Lupus
CLICK TO READ ORIGINAL ARTICLE > by Fariss Samarrai, farisss@virginia.edu Lupus is a complex autoimmune disease that affects more than 1.4 million Americans. Its treatment in the United States alone costs about $7 billion per year. Despite this impact and cost, the...
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
CLICK FOR ORIGINAL ARTICLE > AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. CHARLOTTESVILLE, Va., July 9, 2019 /PRNewswire/ -- AMPEL BioSolutions today...
Trial of LuPRO mobile app predicts Lupus flares
CLICK TO VIEW ORIGINAL ARTICLE > BY KATIE O'CONNOR, Richmond Times-Dispatch In 50 years, only one treatment was approved by the U.S. Food and Drug Administration to treat lupus, an autoimmune disease in which a person’s immune system attacks their healthy organs...
Local Biomedical Company Battling Lupus On Many Fronts
A Charlottesville company is helping to lead a global scientific effort to better understand and treat lupus, an autoimmune disease sometimes called “the cruel mystery.”
LUPUS NEWS
Machine Learning Approaches to Predict Lupus Disease Activity from Gene Expression Data
The integration of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a significant challenge because of the high degree of heterogeneity among patients and study cohorts, especially those collected on different microarray...
Doctors and patients monitor Lupus with mobile app
CLICK TO VIEW ORIGINAL ARTICLE > by Josh Mandell A Charlottesville company is helping to lead a global scientific effort to better understand and treat lupus, an autoimmune disease sometimes called “the cruel mystery.” AMPEL Bio Solutions, a biomedical...
Digital Dialogue: Lupus Awareness Month
For Lupus Awareness Month in May, NBC12 hosted a Digital Dialogue Tuesday night featuring advocates and specialists in the Lupus field, treatment, coping with the disease, finding a cure and new advancements being pioneered right here in Virginia.
Lupus: the right drug for the right person at the right time
On average, it takes nearly six years for people with Lupus to be diagnosed from the time they notice their first symptoms. May is Lupus Awareness month, and Dr. Amrie Grammer, co-founder of Ampel BioSolutions talks with Wendy about the state of Lupus treatments and...
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
CLICK TO READ THE ARTICLE > CHARLOTTESVILLE, Va., July 9, 2019 /PRNewswire/ -- AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. Revealed in the...
Alterations in Macrophage Activation May Signal a Lupus Flare
By Lara C. Pullen, PhD CLICK TO VIEW ARTICLE > Rheumatologists lack a definitive diagnostic tool to determine whether a patient has systemic lupus erythematous (SLE) and/or when a patient will experience a lupus flare. New data suggest myeloid cells in SLE patients...
The state of lupus treatments and what the future looks like.
Les Sinclair talks with Dr. Amrie Grammer about AMPEL BioSolutions, a Charlottesville Virginia company that has reengineered the gene-based technology they developed for lupus to COVID19.
A Sister’s Story: New Hope in Her Twin’s Cruel Struggle With Lupus
CLICK TO VIEW ARTICLE > > Lupus Awareness Biotechnology Charlottesville Virginia Twins AMPEL Biosolutions Innovation University There is nothing better in the world than having a twin sister. We get to share clothes and shoes, and have a lifelong best friend....
Data mining could lead to therapy advances
Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.